Purpose: Robust optimization (RO) methods are applied to intensity-modulated proton therapy (IMPT) 13 treatment plans to ensure their robustness in the face of treatment delivery uncertainties, such as 14 proton range and patient setup errors. However, the impact of those uncertainties on the biological 15 effect of protons has not been specifically considered. In this study, we added biological effect-based 16 objectives into a conventional RO cost function for IMPT optimization to minimize the variation in 17 biological effect. 18
Introduction
because existing experimental biological data are insufficient to clearly correlate RBE and dose perdenote the maximum and minimum LET-weighted dose, respectively, over all nine scenarios of voxel ,where indicate the product of dose and LET for voxel in scenario . 132 = ∑ (1 + ) 2 = + (6) 133
To reduce the variation in biological effect in each voxel , we propose to add minimization of 134 the uncertainty gap, i.e., In this study, PTV-based optimization, conventional RO, and BioRO models were solved by a quasiclinical cases: a brain tumor case, a prostate tumor case and a head & neck tumor case (Table 1) . For the 151 brain tumor case, three sets of angle combinations (gantry and couch) were used: (260°, 10°), (100°, 152 350°) , and (180°, 0°). Setup uncertainties of ± 3 mm in three dimensions and range uncertainties of ± 153 3.5% of the nominal range were assumed. Two beams, (90°, 0°) and (270°, 0°), were used for the 154 prostate tumor case, with setup uncertainties of ± 5 mm and range uncertainties of ± 3.5% of the 155 nominal range. Similarly, setup uncertainties of ±3 mm and range uncertainties of ± 3.5% of the beams' 156 nominal range were assumed in the head and neck tumor case under three beams: (180°, 0°), (65°, 345°) 157 and (300°, 20°). Therefore, both RO and BioRO considered nine scenarios, i.e., one nominal scenario 158 (without the consideration of uncertainties), and eight uncertainty scenarios, including six setup 159 uncertainty scenarios by shifting the patient's CT image (Albertini et al 2011) and two range uncertainty 160 scenarios by scaling the nominal beamlet ranges (Schaffner and Pedroni 1998). The prescribed dose to 161 target volumes and field arrangements were the same as those used in the clinical treatments. More 162 planning details are listed in Table 1 . The doses prescribed to all OARs were set to 0 in the optimizations. 163
Upon the completion of the optimization step for each of the three approaches, fixed RBE (1.1)-164 weighted dose (RWD) and LETxD were calculated for each of the nine scenarios. Note that each of the 165 three plans was normalized to have 98% of the CTV covered by the prescribed dose. Dose-volume 166 histograms (DVHs) and LETxD-volume histograms for the nominal scenario were used to quantify the 167 plans' quality. To evaluate and compare the plan robustness, the envelope of all DVHs or LETxD-volume 168 histograms in band graphs (Trofimov et al. 2010 ) and maps of the uncertainty gap for all nine scenarios 169 were displayed. The difference between the worst and best value of a DVH point, such as Dv%, is 170 considered as the bandwidth at Dv% for a given organ. Figure 1 shows the DVH and LETxD volume histogram bands for the CTV and the brainstem forthe three differently optimized IMPT plans in the brain tumor case. The DVH bands for the CTV were 174 narrower for the RO and BioRO plans than for the PTV-based plan, indicating that the RO and BioRO 175 plans were less sensitive to setup and range uncertainties than was the PTV-based plan. As we expected, 176 the BioRO approach was able to generate robust physical dose distributions in the target volume that 177 were comparable to those generated by the RO approach. Moreover, the DVH bands for the brainstem 178 were similar for all three optimization techniques. We should note that the mean dose to the brainstem 179 increased from 25.9 Gy with the RO plan to 27.8 Gy with the PTV-based plan and 28.3 Gy with the BioRO 180 plan. However, the maximum dose to the brainstem was similar in all three plans; the maximum values 181 (worst-case) of D2% were 57.9 Gy, 54.5 Gy, and 54.8 Gy for the PTV-based, RO, and BioRO plans, 182 respectively (Table 2) . 183
In contrast, LETxD volume histogram bands of the three plans exhibited pronounced differences 184 (Figure 1 ). The robustness of the LETxD distributions in both the CTV and the brainstem was markedly 185 improved by the BioRO approach. For instance, the bandwidth at D98% of c LETxD in the CTV was 0.4 Gy 186 anatomy and the beam arrangement. The bandwidth at D2% of c LETxD in the bladder was 1.7 Gy for theBioRO plan, smaller than the 3.8 Gy and 2.2 Gy bandwidths for the PTV-based plan and the RO plan, 198 respectively (Table 3) was the most robust in terms of physical dose distribution in the target and brainstem. Moreover, thein the brainstem. Meanwhile, the robustness of the physical dose distribution for the BioRO plan wasimproved compared to the PTV-based plan. 222
As shown in Figure 4 , the biological effect in the nominal scenario was the lowest for the BioRO 223 plan, especially in critical organs. However, there was almost no difference among the three plans in the 224 physical dose distributions for the nominal scenario (see subfigure (a-b), (a-c) and (b-c)). 225
Discussion 226
Three has been a growing interest in LET-based IMPT planning, including novel forward planning 227 techniques and optimization methods (An et al. 2017; Bassler et al. 2010; Cao et al. 2018; Fager et al. 228 2015; Giantsoudi et al. 2013; Grassberger et al. 2011; Inaniwa et al. 2017; Unkelbach et al. 2016) . The 229 primary goal of LET-based planning is to place areas of higher LET to achieve a greater biological effect in 230 radioresistant tumors while minimizing LET in critical structures to avoid unnecessary tissue damage. At 231 the same time, LET-based planning keeps physical dose distributions as similar as possible to those 232 currently used in proton therapy with fixed RBE planning. These methods have demonstrated the 233 potential of increasing LET in target regions and/or reducing LET in normal tissues without excessively 234 compromising current dose requirements. However, the challenge of IMPT delivery uncertainties has 235 been largely ignored. The BioRO approach to IMPT planning proposed in the present study focuses on 236 minimizing the variation in biological effect attributable to physical uncertainties for both target and 237 normal tissues. The uncertainty gap minimization method was effective in reducing the spread of LETxD-238 volume histogram bands in this study. In other words, this approach could produce treatment plans with 239 a high certainty of biological effect with satisfactory physical dose plan quality. 240 RO has been shown to deliver IMPT more safely than conventional PTV-based optimization 241 (Fredriksson, Forsgren, and Hårdemark 2011; Liu et al. 2012; Lowe et al. 2017; Pflugfelder, Wilkens, and close to the target boundary. Therefore, researchers have proposed that unlike PTV-based plans, RO 245 plans may alleviate increased LET or LETxD in OARs adjacent to the target (Giantsoudi et al. 2017) . Our 246 study confirmed that this is the case. For example, compared to the PTV-based plan, LETxD for 2% of the 247 volume and mean LETxD for the brainstem were reduced by 15% and 11%, respectively, with RO. 248
Similarly, LETxD for 2% of the volume and mean LETxD for the rectum were reduced by 33% and 43%, 249 respectively. 250
Interestingly, the BioRO plan further reduced LETxD in OARs than the RO plan for both patient 251 cases. For example, for the brain tumor case, compared to the PTV-based plan, LETxD for 2% of the 252 volume and mean LETxD for the brainstem were reduced by 48% and 43%, respectively. Similarly, for 253 the prostate tumor case, LETxD for 2% of the volume and mean LETxD for the rectum were reduced by 254 40% and 43%, respectively. This finding may be nonintuitive, as minimization of LETxD was not specified 255 in the BioRO cost function. Instead, the uncertainty gap of LETxD was minimized. We conjecture that the 256 reduction of LETxD in BioRO plans is attributable to the positive correlation between the uncertainty gap 257 of LETxD and the nominal LETxD. For instance, a higher LETxD leads to a larger uncertainty gap, as either 258 nominal LETxD or LETxD in various uncertainty scenarios is modulated by the same set of beamlet 259 intensities, i.e., = ∑ 2 . In all patient cases, we found that the sum of all beamlet 260 intensities for the BioRO plan was the lowest among the three plans. However, these reduced total 261 intensities did not necessarily lead to a cold plan in terms of dose, as seen in this study, because of the 262 solution degeneracy of IMPT optimization. 263
We also note that our method is similar to ones proposed by Giantsoudi et al (2017) and An et al 264 (2017) in which biological effect was included in the robust optimization framework. But our method is 265 different in terms of its objectives that minimize the impact of physical uncertainties on biological effect,i.e., those uncertainty gap terms, instead of minimizing worst-case biological effect. The differenceamong methods is worth investigating in future studies. Moreover, the information gap concept could 268 also be applied in the robust optimization of dose, compared to the worse case optimization strategies 269 extensively used in the literature. However, this may require a comprehensive comparison study and is 270 beyond the scope of this paper concerning biological effect robustness. 271
Moreover, the BioRO plan also reduced LETxD in the target for all patient cases. However, the 272 reduction in the target dose was much smaller than it was in OARs. The main reason for this difference 273 may be that the BioRO plan enforced the requirement of prescribed dose to the target, but not to OARs, 274 for which there was no lower dose limit. One straightforward method to avoid the reduction of LETxD in 275 the target could be to use an additional objective to maximize the nominal or minimum LETxD for target 276 voxels. Such a method for managing the trade-off between optimality and robustness with regard to 277 biological effect needs to be explored in future research. 278
The gain in LET or LETxD while maintaining dose requirements is mainly achievable because 279
IMPT provides a higher degree of freedom for optimization, i.e., intensity modulation. Our study 280 demonstrated that plan robustness to biological effect can be improved by redistributing LETxD. 281
Similarly, previous studies showed that LET and LETxD were improved by redistributing them (Cao et al. 
